Wood, W. A., Deal, A. M., Battaglini, C. L., Reeve, B. B., Abernethy, A. P., Kim, Y. H., … Shea, T. C. (2012). Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT). In Blood (Vol. 120, pp. 4152–4152). American Society of Hematology. https://doi.org/10.1182/blood.v120.21.4152.4152

Wood, William A., Allison M. Deal, Claudio L. Battaglini, Bryce B. Reeve, Amy P. Abernethy, Yoon Hie Kim, Julia S. Whitley, et al. “Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT).” In Blood, 120:4152–4152. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.4152.4152.

Wood WA, Deal AM, Battaglini CL, Reeve BB, Abernethy AP, Kim YH, et al. Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT). In: Blood. American Society of Hematology; 2012. p. 4152–4152.

Wood, William A., et al. “Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT).” Blood, vol. 120, no. 21, American Society of Hematology, 2012, pp. 4152–4152. Crossref, doi:10.1182/blood.v120.21.4152.4152.

Wood WA, Deal AM, Battaglini CL, Reeve BB, Abernethy AP, Kim YH, Whitley JS, Shatten C, Irons RN, Essenmacher AN, Wehner K, Pinto A, Coghill J, Armistead PM, Sarantopoulos S, Gabriel DA, Serody JS, Shea TC. Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT). Blood. American Society of Hematology; 2012. p. 4152–4152.